mauiguy2
4 년 전
Hard to say what will happen on August 1. But, one thing for sure, Linton is too shrewd to immediately dump all his shares on that date. He's been around the block a few times. Whenever he decides to sell his shares, he'll try to maximize his profit. And, most likely, he would do it over time. This type of situation certainly isn't unusual in the stock world.
mauiguy2
4 년 전
i wonder what the real story is between VREOF and Bruce Linton. It seems to me that he made out like a bandit with his "divorce" from VREOF. But, the market seems to like the news released late yesterday. So, I like it, too!
The funny thing, though, is that the hiring of Bruce Linton was the only reason I bought my VREOF shares. But, the PPS floundered with him at the helm. When he was let go, I seriously considered selling my shares. But a strange thing happened after he left VREOF. Not long after his departure, the PPS began to flourish and the company is doing just fine.
Anyway, all of this is a big head-scratcher to me. But, like I said, if the market is fine with Linton's severance package, I am, too.
https://finance.yahoo.com/news/vireo-health-former-executive-chairman-230000969.html
Vireo Health and Former Executive Chairman Enter into Mutual Release
MINNEAPOLIS, March 31, 2021 /PRNewswire/ -- Vireo Health International Inc. ("Vireo" or the "Company") (CNSX: VREO; OTCQX: VREOF), a leading physician-led, science-focused, multi-state cannabis company, today announced that it has entered into a mutual release (the "Mutual Release") with Bruce Linton, a globally recognized authority in cannabinoid policy and business and the Company's former Executive Chairman, relating to all outstanding matters between them.
Mr. Linton joined Vireo in November of 2019. On June 8, 2020, the Company elected to terminate its employment agreement with Mr. Linton as Executive Chairman, on an entirely without-cause basis. In connection with Mr. Linton's employment agreement, Mr. Linton received warrants (the "Warrants") to acquire up to 15 million subordinate voting shares (each, a "Share") in the Company. 10 million of the Warrants (the "First Tranche Warrants") have an exercise price of US$1.02 per Share.
As part of the Mutual Release, Vireo has issued 8,000,000 Shares to Mr. Linton. 7,110,381 Shares were issued to Mr. Linton pursuant to the exercise of the First Tranche Warrants on a cashless basis. The remaining 889,519 Shares were issued to Mr. Linton pursuant to a private placement exemption resulting in no cash consideration being paid to Vireo. The Shares issued pursuant to the First Tranche Warrants are free of trading restrictions and the 889,519 Shares are subject to a hold period expiring on August 1, 2021. In addition, as part of the Mutual Release, Mr. Linton has surrendered all right, title and interest in all other Warrants for cancellation.
The issuance of Shares pursuant to the Debt Settlement constitutes a "related party transaction" as this term is defined in Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions ("MI 61-101"). All of the independent directors of the Company, acting in good faith, determined that the fair market value of the Shares being issued pursuant to the Debt Settlement and the consideration being paid is reasonable. The Company intends to rely on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 as neither the fair market value of the Shares nor the debt exceeds 25% of the Company's market capitalization. The Company did not file a material change report more than 21 days before the expected closing of the Debt Settlement as the details and amounts of debts settled under the transaction were not finalized until closer to the closing and the Company wished to close the Debt Settlement as soon as practicable. All Shares issued to pursuant to the Debt Settlement will be subject to a four (4) month hold period.
JohnCM
4 년 전
Three months Sept 30th 2020
EBITDA, as described in accompanying disclosures and footnotes, was $8.1 million during Q3 2020, compared to a loss of $15.9 million in Q3 2019. Adjusted EBITDA was a loss of $675,808 in Q3 2020, as compared to a loss of $5.2 million in Q3 2019. Please refer to the Supplemental Information and Reconciliation of Non-IFRS Financial Measures at the end of this press release for additional information.
Net income in Q3 2020 was $122,252, as compared to a net loss of $14.6 million in Q3 2019. The favorable improvement in net income was primarily driven by the one-time gain of $16.4 million on the divestiture of the Company's former PAMS subsidiary.